Featured News

Notables 2020

Thomas J. Baranski, MD, PhD has received an NIH R01 award. This is a mutual PI award with Mike Provence, PhD and Heather Lawson, PhD in the Department of Genetics. The researchers will use a high-throughput method to manipulate hundreds of suspected genes to hone in on the biology behind the human findings, which could lead to new therapies and prevention approaches for obesity. ($1,281,798)

Paulina Cruz Bravo, MD has received a Partnership Development & Sustainability Support (PDSS) from ICTS. This mechanism provides ICTS investigators and their community partner(s) with up to $10,000 over a one-year period to develop the trust, infrastructure, capacity, and skills needed to support future collaborative grant opportunities. ($10,000)

Jing Hughes, MD, PhD has received an NIH K08 supplement for career development. ($50,000) In addition, she received an investigator award from the Diabetes Research Connection, a private foundation that supports innovative research in type 1 diabetes. ($50,000)

Janet B. McGill, MD, MA, FACE  has received funding from Jaeb Center for Health Research Foundation to study the insulin-only bionic pancreas hybrid closed loop system. ($279,490)

Jeffrey R, Millman, PhD has received the WU & BJHF Grant Funding for Research in Transplantation. The research team will be evaluating the effects of several key transplantation parameters on the effectiveness of insulin-producing islets derived from stem cells to cure diabetes. ($50,000)

Brian Muegge, MD, PhD has received a VA Career Development Award. This award supports Dr. Muegge’s research program studying the development and response of intestinal endocrine cells to injury and disease. ($1,145,420)

Maria Remedi, PhD has received an NIH R01. Reduction of pancreatic insulin-containing cells and therefore antidiabetic drug responsivity are key events in the pathogenesis and progression of diabetes. The main goal of this proposal seeks to understand the mechanisms underlying loss of insulin-containing cells in diabetes, and to explore novel approaches to prevent this loss and therefore restore antidiabetic drug responsivity. The outcomes of this grant will have direct relevance to the progression and therapy of human diabetes. ($1,000,000)